The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
King Charles in the German Parliament gave support to the development of the Hydrogen economy to tackle climate change
https://isirv.org/site/index.php/component/content/article/9-events/570-7th-isirv-avg-abstract-submission
I wonder if they will present an abstract ref Host Directed Antiviral Therapeutics
Apologies if already posted
https://www.gov.uk/government/news/mhra-to-streamline-clinical-trial-approvals-in-biggest-overhaul-of-trial-regulation-in-20-years
https://www.bbc.co.uk/iplayer/live/bbcnews
Watch around 10:50 also referenced COPD SNG is still very much in the game
Back on the Oz theme very interesting article albeit 6 months old
https://endpts.com/from-australia-new-173m-research-center-strives-to-be-at-the-forefront-of-pandemic-drug-discovery/
“We need those technologies because with the existing technologies, there isn’t a way to speed up what we currently do,” she said, adding that three approaches appear promising: nucleic acid therapeutics, treatments that modulate the innate immune response, and developing cheaper and simpler-to-use antibody therapies "
Interesting
I see SAR having been delayed by MHRA in UK for a P1a trial have sought CTA application in Australia and expect approval in Q2
from the RNS
Australia offers state-of-the-art research facilities and an efficient approval process, making it an attractive location for research and development. Moreover, the country provides significant tax incentives for companies that conduct their research in Australia, allowing them to claim up to 43.5% of their eligible R&D expenditure as a cash payment. As such, Sareum has established the required local presence by setting up a legal entity in Australia
Just a reminder .The CEO of Shionogi put forward a hypothesis that their drug will prevent the development of Long Covid but will have to have proof of this .It is very frustrating that Synairgen produced unique LC data back in September and praised by Prof Chris Brightling .
"Shionogi the company says interim results of a study suggest taking the pill could lessen a patient’s chances of developing long COVID-19."
“If you kill the virus fast enough and sharp enough, the lower the probability of long COVID. That’s our hypothesis, but we need to prove that,” Teshirogi said in an interview.
https://discover.bmw.co.uk/article/step-inside-the-new-bmw-ix5-hydrogen
Some interesting historic facts from Activ 2 PDF . Synairgen has done decades of the spade work in research surely something of benefit must materialise from this
"Nebulized SNG001 (36 MIU) effectively decreased lung tissue viral load pre- and postinfection with 2009 pandemic H1N1 influenza as compared to placebo, when measured using molecular methods [6]. Six of nine placebo recipients but none of the animals treated with SNG001 experienced a severe fever. Correspondingly, significantly fewer
areas of lung tissue stained positively for influenza in pre- and post-infection treatment
groups compared to placebo (semi-quantitatively scoring of lung tissue sections by
immuno-histochemistry staining using an antibody directed against the influenza
nucleoprotein). Macroscopic examination of SNG001-treated animals showed their lungs
were less affected, having fewer lesions than placebo-treated animals. Alveolar
histopathology scores relating to lung inflammation, hemorrhage, edema, and
pneumocyte hyperplasia were lower in SNG001-treated animals (Synairgen’s study
report SR043) [5]. "
https://fnih.org/sites/default/files/2021-10/ACTIV-2_v7.0-wLOA%20073021.pdf